

1

2

3

4 **Glucose and lipid profiles in men with non-obstructive**

5 **azoospermia**

6

7

8 Ponco Birowo<sup>1\*</sup>, Dimas Tri Prasetyo<sup>1</sup>, Dwi Ari Pujianto<sup>2</sup>, Widi Atmoko<sup>1</sup>, Nur

9 Rasyid<sup>1</sup>

10

11

12

13 <sup>1</sup> Department of Urology, Faculty of Medicine Universitas Indonesia - Dr. Cipto

14 Mangunkusumo Hospital, Jakarta

15

16 <sup>2</sup> Department of Medical Biology, Faculty of Medicine Universitas Indonesia,

17 Jakarta

18

19 \* Corresponding author

20 Email: [ponco.birowo@gmail.com](mailto:ponco.birowo@gmail.com)

21 Running title: Glucose and lipid profiles in men with non-obstructive azoospermia

## 22 **Abstract**

23 The impact of a low testosterone level among men with non-obstructive  
24 azoospermia with various testicular histopathological patterns on the regulation of  
25 glucose and lipid metabolism is less well known than among the general population.  
26 The aim of this retrospective study was to examine the association between  
27 testicular histopathology and components of the metabolic profile among men with  
28 non-obstructive azoospermia. Participants were divided into two groups: men with  
29 non-obstructive azoospermia and men with obstructive azoospermia. Testicular  
30 biopsies were performed among those with non-obstructive azoospermia. We  
31 included 115 patients in this study: 83 (72.2%) had non-obstructive azoospermia  
32 and 32 (27.8%) had obstructive azoospermia. The plasma glucose concentration,  
33 glycated hemoglobin level, and lipid profile were similar between patients with  
34 non-obstructive azoospermia and those with obstructive azoospermia. Upon  
35 subgroup analysis of patients with non-obstructive azoospermia, those with Sertoli-  
36 cell-only syndrome had the lowest testosterone ( $431 \pm 238$  ng/dL;  $P=0.039$ ) and  
37 highest follicle-stimulating hormone ( $23.4 \pm 18.2$  mIU/mL;  $P=0.002$ )  
38 concentrations. They also had the highest triglyceride concentration ( $163 \pm 114$   
39 mg/dL;  $P=0.001$ ). Interestingly, patients with Sertoli-cell-only syndrome had a  
40 lower fasting plasma glucose concentration ( $92 \pm 11$  mg/dL;  $P<0.001$ ) and glycated  
41 hemoglobin level ( $5.9 \pm 0.8\%$ ;  $P=0.022$ ) than those with histopathological patterns  
42 of maturation arrest and hypospermatogenesis. In conclusion, differences in

43 glucose and lipid metabolism are evident between men with non-obstructive  
44 azoospermia with different spermatogenesis patterns.

45

46 **Key Words:** azoospermia; NOA; OA; serum testosterone; metabolic profile.

47

## 48 **Introduction**

49 The association between testosterone and the development of type-2  
50 diabetes mellitus (DM), obesity, and dyslipidemia has been demonstrated [1–6].  
51 Testosterone deficiency is reportedly related to metabolic syndrome [7]. The exact  
52 mechanism by which testosterone may affect the metabolic profile is yet to be  
53 established.

54 Testosterone is thought to have protective effects against the pathogenesis  
55 of metabolic syndrome and its components by increasing skeletal muscle tissue and  
56 decreasing abdominal obesity and the levels of nonesterified fatty acids in the body  
57 [8]. Testosterone reportedly has a favorable effect on vascular reactivity,  
58 inflammation, cytokine production, and the expression of adhesion molecules, as  
59 well as on the serum lipid concentration and hemostatic factors [9].

60 Despite the fact that there have been numerous studies in which the  
61 association between testosterone and the metabolic profile has been investigated,  
62 its effect on the regulation of glucose and lipid metabolism in infertile men with  
63 non-obstructive azoospermia (NOA), particularly in relation to testicular

64 histopathology, is less well known. Thus, the aim of this study was to examine the  
65 effect of testosterone level on the plasma glucose and lipid profiles of men with  
66 NOA, as well as its impact based on testicular histopathology patterns. We revealed  
67 that the presence of testicular damage in NOA is associated with lower serum  
68 testosterone and higher levels of follicle-stimulating hormone (FSH), as well as  
69 lower fasting plasma glucose and higher triglyceride levels than the absence of such  
70 damage.

71

## 72 **Material and methods**

### 73 **Patient selection**

74 In this retrospective study, we included all men with azoospermia seeking infertility  
75 treatment at the Urology Clinics of Dr. Cipto Mangunkusumo Hospital and Bunda  
76 Hospital (Jakarta, Indonesia) from 2016 to 2020. Azoospermia is defined as the  
77 absence of spermatozoa in the seminal fluid after centrifugation. The diagnosis was  
78 made only when no spermatozoa was found in two consecutive semen analyses, each  
79 after 2-7 days of sexual abstinence. Patients who were recruited into this study did not  
80 have any prior history of type-2 DM or dyslipidemia and did not take any medication  
81 that may affect glucose or lipid metabolism in the 3 months before recruitment. Patients  
82 were excluded if had any prior history of type-2 DM, dyslipidemia, and taking any  
83 medication that may affect glucose or lipid metabolism in the 3 months before

84 recruitment. Type-2 DM is defined as 1) having a fasting plasma glucose concentration  
85 of  $\geq 126$  mg/dL, or 2) 2-hour plasma glucose  $\geq 200$  mg/dL (11.1 mmol/L) during oral  
86 glucose tolerance test, or 3) A1C  $\geq 6.5\%$  (48 mmol/mol), or 4) experiencing classical  
87 symptoms of hyperglycemia or hyperglycemic crisis (polyuria or polydipsia) and  
88 having a random plasma glucose concentration  $\geq 200$  mg/dL [10]. Dyslipidemia is  
89 defined as a history of exhibiting either a total cholesterol concentration  $\geq 200$  mg/dL,  
90 a high-density lipoprotein (HDL) cholesterol concentration  $< 40$  mg/dL for men and  
91  $< 50$  mg/dL for women, or a triglyceride concentration  $> 150$  mg/dL [11]. There were  
92 two study groups in this study: patients with NOA and those with obstructive  
93 azoospermia (OA). The NOA/OA diagnosis was based on the patient history, clinical  
94 examination, and reproductive hormone (follicle-stimulating hormone [FSH],  
95 luteinizing hormone, and testosterone) assessment, and confirmed in a testicular  
96 histopathology specimen taken during sperm retrieval procedures. This study was  
97 approved by the Ethics Committee of the Faculty of Medicine, Universitas Indonesia  
98 and complies with the Code of Ethics of the World Medical Association (Declaration  
99 of Helsinki 1964, revised 20033 and Declaration of Tokyo 1975, revised 20064).  
100 Informed consent from participants were not required due to retrospective data  
101 collection.

102

## 103 **Study design**

104 We conducted hormonal and metabolic evaluations of all participants, which  
105 included concentrations of serum testosterone, serum FSH, fasting plasma glucose,  
106 glycated hemoglobin (HbA1c), total cholesterol, low-density lipoprotein (LDL), high-  
107 density lipoprotein (HDL), and triglyceride. Participants were asked to fast for 10-12 h  
108 before their blood was drawn. Serum testosterone was examined by using an  
109 electrochemiluminescence immunoassay (Roche, Basel, Switzerland). Serum FSH was  
110 examined by using immunochemiluminescence (Siemens Healthineers, Erlangen,  
111 Germany). Fasting plasma glucose was measured by using the hexokinase method  
112 (Diatron Promedika, Jakarta, Indonesia). HbA1c was examined by using an enzymatic  
113 assay (Abbott Architect, Illinois, USA). Total cholesterol was measured by using the  
114 cholesterol oxidase-peroxidase aminoantipyrine technique, LDL and HDL were  
115 examined by using homogeneous assays, and triglyceride was measured by using  
116 glycerol peroxidase phosphate method (all reagents for lipid profiling were from  
117 Diatron Promedika). The serum testosterone concentration was presented as  
118 nanograms/deciliter (ng/dL), the FSH concentration was presented as milli-  
119 international units per milliliter (mIU/mL), while the fasting plasma glucose, total  
120 cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride concentrations were  
121 presented as milligrams/deciliter (mg/dL). HbA1c was presented as a percentage (%).

122

## 123 **Testicular biopsy**

124 We also performed surgical sperm retrieval by using testicular sperm extraction  
125 (TESE) for patients with NOA as a part of their infertility treatment. TESE was  
126 performed by making a small incision on the avascular plane of the testis and collecting  
127 a small portion of the testicular tissue for examination for the presence of motile  
128 spermatozoa under an electric light microscope.

129 We also performed a second testicular biopsy for histological examination of the  
130 testicular phenotype (spermatogenesis pattern). Samples were added into a Bouin's  
131 solution and sent to the laboratory for examination. In the laboratory, several sections  
132 of the samples were prepared and stained in paraffin blocks. The section with the  
133 highest concentration of seminiferous tubules was examined by the same laboratory  
134 analyst for all samples under a light microscope. Testicular histopathological patterns  
135 were divided into three categories (Fig 1): (i) Sertoli cell only (SCO; absence of germ  
136 cells in the seminiferous tubules), (ii) maturation arrest (incomplete spermatogenesis),  
137 and (iii) hypospermatogenesis (a reduced number of normal spermatogenic cells). All  
138 sperm retrieval and testicular biopsy procedures were performed by the same surgeon,  
139 while all testicular histopathological examinations in this study were performed in the  
140 same laboratory by the same examiner.

141

142 **Fig 1. Classification of spermatogenesis based on testicular histopathological**  
143 **patterns.** A. Sertoli cell only (#). B. Maturation arrest with spermatocyte cells (\$). C.  
144 Hypospermatogenesis, which is marked by a decreased number of normal



145 spermatozoa (^). Courtesy of the Department of Biology, Faculty of Medicine,  
146 Universitas Indonesia, Jakarta.

147

## 148 **Statistical analysis**

149 All continuous data were presented as mean and standard deviation value as it met  
150 the normality distribution assumption by using Shapiro-Wilk test. No outlier was  
151 removed from the analysis. We compared the results of the hormonal and metabolic  
152 evaluations between patients with NOA and those with OA by using the two-tailed  
153 independent t-test. We performed subgroup analysis within the NOA group based on  
154 the testicular histopathological patterns by using one-way analysis of variance and  
155 post-hoc Bonferroni test. Minimum sample size is 30 for each group based on  
156 hypothesis testing for two mean formula (power 80%, alpha 5%) [12]. All statistical  
157 analyses were performed by using IBM SPSS Statistics for Windows version 20.0  
158 (IBM Corp., Armonk, NY, USA) [13], with  $P < 0.05$  considered statistically significant.

159

## 160 **Results**

161 We included 115 patients in this study, of which 83 (72.2%) were in the NOA group  
162 and 32 (27.8%) were in the OA group. The age range of patients was 26-72 years and  
163 there were no significant differences in age or body mass index between the two study  
164 groups (Table 1).

165

166 **Table 1. Comparisons of hormonal and metabolic parameters between patients**

167 **with NOA and those with OA**

Parameter	NOA (n = 83)	OA (n = 32)	<i>P</i> value
Age (years)	36 ± 7	38 ± 9	0.308 / <i>t</i> = 1.024
BMI (kg/m <sup>2</sup> )	26.7 ± 5.4	27.7 ± 5.5	0.632 / <i>t</i> = 0.483
<b>Serum testosterone (ng/dL)</b>	<b>442 ± 181</b>	<b>511 ± 126</b>	<b>0.049 / <i>t</i> = 1.970</b>
<b>FSH (mIU/mL)</b>	<b>16.3 ± 13.8</b>	<b>4.3 ± 1.1</b>	<b>&lt;0.001 / <i>t</i> = -4.879</b>
Fasting plasma glucose (mg/dL)	98 ± 32	90 ± 10	0.143 / <i>t</i> = -1.476
HbA1c (%)	6.1 ± 1.4	5.4 ± 0.4	0.132 / <i>t</i> = -1.534
Total cholesterol (mg/dL)	203 ± 34	197 ± 53	0.462 / <i>t</i> = -0.738
LDL (mg/dL)	143 ± 38	159 ± 44	0.240 / <i>t</i> = 1.188
HDL (mg/dL)	42.8 ± 9.1	43.9 ± 8.5	0.574 / <i>t</i> = 0.564
Triglyceride (mg/dL)	145 ± 81	124 ± 44	0.159 / <i>t</i> = -1.417

168

*P* values were calculated with the two-tailed independent t-test and degree of freedom 113 All results are presented

169

as the mean ± standard deviation.

170

NOA = non-obstructive azoospermia; OA = obstructive azoospermia; BMI = body mass index; FSH = follicle-

171

stimulating hormone; HbA1c = glycated hemoglobin; HDL = high-density lipoprotein; LDL = low-density

172

lipoprotein.

173

174 Patients with NOA had significantly lower serum testosterone and higher FSH  
175 concentrations compared to those with OA (Table 1). Furthermore, no significant  
176 differences were observed in glucose and lipid profiles between the two study groups.  
177 Among patients with NOA, patients with SCO testicular histopathology had the lowest  
178 serum testosterone ( $431 \pm 238$  ng/dL;  $P=0.039$ ) and highest FSH ( $23.4 \pm 18.2$  mIU/mL;  
179  $P=0.002$ ) concentrations (Table 2). Patients with SCO had a lower total cholesterol  
180 than those with maturation arrest and hypospermatogenesis ( $185 \pm 29$  mg/dL,  $208 \pm 35$   
181 mg/dL, and  $215 \pm 31$  mg/dL, respectively;  $P=0.008$ ). A comparison of LDL levels  
182 among those groups yielded similar results ( $122 \pm 25$ ,  $160 \pm 18$ , and  $146 \pm 8$ ,  
183 respectively;  $P=0.012$ ).

184

185 **Table 2. Comparisons of hormonal and metabolic parameters among patients**  
186 **with NOA based on testicular histopathological patterns**

Parameter	SCO (n = 24)	Maturation arrest (n = 40)	Hypospermatogenesis (n = 19)	P value
Age (years)	$34.8 \pm 6.5$	$36.6 \pm 7.2$	$38.8 \pm 7.2$	0.194
BMI (kg/m <sup>2</sup> )	$22.7 \pm 3.1$	$29.1 \pm 4.9$	$28.4 \pm 6.1$	0.141
<b>Serum testosterone (ng/dL)</b>	<b><math>431 \pm 238</math></b>	<b><math>441 \pm 157</math></b>	<b><math>455 \pm 152</math></b>	<b>0.039*</b>

	<b>23.4 ±</b>	<b>14.3 ±</b>		
<b>FSH (mIU/mL)</b>	<b>18.2</b>	<b>11.6</b>	<b>11.8 ± 8.3</b>	<b>0.009**</b>
Fasting plasma glucose (mg/dL)	92 ± 11	101 ± 42	102 ± 27	0.559
HbA1c (%)	5.9 ± 0.8	6.2 ± 1.8	6.1 ± 1.7	0.874
<b>Total cholesterol (mg/dL)</b>	<b>185 ± 29</b>	<b>208 ± 35</b>	<b>215 ± 31</b>	<b>0.008***</b>
<b>LDL (mg/dL)</b>	<b>122 ± 25</b>	<b>160 ± 18</b>	<b>146 ± 8</b>	<b>0.012***</b> *
HDL (mg/dL)	40.3 ± 8.1	44.5 ± 9.3	42.5 ± 9.4	0.203
Triglyceride (mg/dL)	163 ± 114	141 ± 68	132 ± 51	0.417

187 \*Post-hoc analysis (Bonferroni test) significant between SCO and hypospermatogenesis ( $P = 0.032$ ), \*\*between  
 188 SCO and maturation arrest ( $P = 0.028$ ) and SCO and hypospermatogenesis ( $P = 0.017$ ), \*\*\*between SCO and  
 189 maturation arrest ( $P = 0.031$ ) and SCO and hypospermatogenesis ( $P = 0.012$ ), and \*\*\*\* between SCO and  
 190 maturation arrest ( $P = 0.010$ ).  $P$  values were obtained with one-way analysis of variance. All results are presented  
 191 as the mean ± standard deviation.

192 NOA = non-obstructive azoospermia; SCO, Sertoli cell only; BMI = body mass index; FSH = follicle-stimulating  
 193 hormone; HbA1c = glycated hemoglobin; HDL = high-density lipoprotein; LDL = low-density lipoprotein.

194

## 195 Discussion

196 We are aware of only a few studies in which the association between male infertility  
197 and glucose and lipid metabolism was investigated. Our results revealed that NOA was  
198 more common than OA among patients with azoospermia seeking fertility treatment at  
199 our center. This is consistent with previous studies, in which a higher incidence of NOA  
200 than OA was reported among men with azoospermia [14,15]. FSH and testosterone  
201 evaluation are important aspects of the assessment of patients with azoospermia, to, for  
202 example, differentiate between NOA and OA. Typically, men with NOA have higher  
203 FSH and lower testosterone concentrations and a more abnormal pattern of testicular  
204 histopathology than those with OA [16]. Thus, the high FSH and low testosterone  
205 values in men with NOA in our study were expected and consistent with the literature.  
206 The etiologies of and risk factors for NOA include Klinefelter's syndrome,  
207 cryptorchidism, Y-chromosome microdeletion, and Kallmann syndrome [17–19]. The  
208 causes of NOA were not investigated in this study.

209 Although not statistically significant, patients with NOA had a higher triglyceride  
210 level than those with OA ( $145 \pm 81$  mg/dL vs.  $124 \pm 44$  mg/dl;  $P=0.159$ ). This  
211 parameter, however, exhibited statistically significant differences among patients with  
212 NOA with different patterns of spermatogenesis upon testicular histopathology. A  
213 study by Bobjer et al. [20] on patients with hypogonadism and NOA revealed that the  
214 testosterone and triglyceride concentrations were positively correlated ( $P=0.03$ ).  
215 Hypertriglyceridemia and a low HDL concentration was also more commonly detected  
216 in men with azoospermia and oligospermia than in normal controls in a study by

217 Mendoza et al [21]. Calonge et al. [22] also reported a correlation between triglyceride  
218 concentration and infertility, where a higher triglyceride concentration was observed  
219 in patients who were infertile compared to controls (164 vs. 91 mg/dL;  $P<0.01$ ). None  
220 of these studies, however, demonstrated a causal relationship between dyslipidemia  
221 and azoospermia.

222 Despite the limited data available on the association between male infertility,  
223 particularly NOA, and glucose metabolism, many studies have demonstrated a  
224 relationship between plasma glucose concentration/development of type-2 DM and  
225 hypogonadism. Laaksonen et al. [23], who conducted a cohort study on 702 middle-  
226 aged Finnish men without a history of type-2 DM or metabolic syndrome, discovered  
227 that men with testosterone, free testosterone, and sex hormone-binding globulin  
228 concentration in the lower quartile had odds ratios ranging from 1.57 (95% confidence  
229 interval [CI]=0.98-2.50) to 2.89 (95% CI=1.93-4.33) for the development of metabolic  
230 syndrome after an 11-year follow-up, even after adjusting for age, smoking status,  
231 alcohol intake, socioeconomic status, and previous cardiovascular disease. Pitteloud et  
232 al. [22], investigating 60 men (age range: 39-65 years) without a history of testicular  
233 disorder, discovered that testosterone concentration was correlated with insulin  
234 sensitivity. Patients with a low serum testosterone concentration had a threefold higher  
235 prevalence of metabolic syndrome compared to patients with normal serum  
236 testosterone level (90% vs. 29%). Blouin et al. revealed that the effects of declining  
237 dehydroepiandrosterone sulfate, an endogenous androgen, on the metabolic profile  
238 were age dependent, unlike those of serum testosterone [24].

239        There are many other studies in which the association between testosterone and the  
240        metabolic profile was examined. However, most of them were focused on the effects  
241        of type-2 DM on the testosterone level. Corona et al. [25] conducted a meta-analysis  
242        on the association between testosterone and type-2 DM, discovering that patients with  
243        type-2 DM exhibited statistically significantly lower concentrations of plasma  
244        testosterone than non-diabetic individuals. The same group also revealed that both  
245        type-2 DM and metabolic syndrome were independent predictors of a low testosterone  
246        concentration [26].

247        In this study, patients with SCO had the lowest testosterone and highest FSH  
248        concentrations. This was in accordance with a previous study by Yassin et al. [27],  
249        wherein lower testosterone ( $1.7 \pm 1.3$  vs.  $5.0 \pm 2.2$  ng/mL;  $P < 0.001$ ) and higher FSH  
250        ( $20.8 \pm 14.8$  vs  $7.7 \pm 3.9$  mIU/mL;  $P < 0.001$ ) concentrations were found in patients with  
251        SCO syndrome (SCOS) than in fertile men. Another study of 134 patients with SCOS  
252        also revealed low testosterone ( $4.4 \pm 1.6$  ng/mL) and high FSH ( $18.9 \pm 9.0$  mIU/mL)  
253        concentrations [28]. Interestingly, in our study, patients with SCOS had higher total  
254        cholesterol and LDL concentration than patients with maturation arrest and those with  
255        hypospermatogenesis. We are not aware of an existing report to this effect. On the other  
256        hand, the triglyceride concentration was higher in patients with the poorest  
257        histopathologic pattern (SCO), although statistically not significant. This may indicate  
258        that triglyceride metabolism is related to the process of spermatogenesis. Our results  
259        regarding glucose and lipid metabolism among patients with NOA with different

260 patterns of testicular histopathology, however, may not be generalizable, as the number  
261 of patients was relatively modest. Thus, further studies on the association between  
262 different levels of testicular damage and the metabolic profile are warranted, with  
263 larger study samples.

264 In conclusion, the presence of testicular damage in NOA is associated with lower  
265 serum testosterone and higher FSH concentrations, as well as with lower total  
266 cholesterol and LDL concentrations. Further studies are needed to better explain these  
267 phenomena, incorporating larger samples and follow-ups. All the components of  
268 metabolic syndrome, i.e., hypertension, hyperglycemia or insulin resistance, large  
269 waist circumference, and hypercholesterolemia or hypertriglyceridemia, must also be  
270 incorporated in future studies, so that the association between male infertility and the  
271 development of metabolic syndrome can be investigated.

272

## 273 **Acknowledgements**

274 None.

275

## 276 **References**

- 277 1. Daubresse JC, Meunier JC, Wilmotte J, Luyckx AS, Lefebvre PJ. Pituitary-  
278 testicular axis in diabetic men with and without sexual impotence. *Diabetes Metab.*  
279 1978;4(4): 233–7.



- 280           2.     Hamdan FB, Al-Matubsi HY. Assessment of erectile dysfunction in  
281     diabetic patients. *Int J Androl.* 2009;32(2): 176–85.
- 282           3.     Rhoden EL, Ribeiro EP, Teloken C, Souto CA. Diabetes mellitus is  
283     associated with subnormal serum levels of free testosterone in men. *BJU Int.*  
284     2005;96: 867–70.
- 285           4.     Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and  
286     biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations  
287     with bioavailable testosterone and visceral adiposity. *Diabetes Care.* 2007;30(4):  
288     911–7.
- 289           5.     Phillips GB. Relationship between serum sex hormones and glucose,  
290     insulin and lipid abnormalities in men with myocardial infarction. *Proc Natl Acad*  
291     *Sci U S A.* 1977;74(4): 1729–33.
- 292           6.     Haffner SM, Karhapaa P, Mykkanen L, Laakso M. Insulin resistance,  
293     body fat distribution, and sex hormones in men. *Diabetes.* 1994;43(2): 212–9.
- 294           7.     Laaksonen DE, Niskanen L, Punnonen K, Nyysönen K, Tuomainen T-  
295     P, Salonen R, et al. Sex hormones, inflammation and the metabolic syndrome: a  
296     population-based study. *Eur J Endocrinol.* 2003;149(6): 601–8.
- 297           8.     Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, et al.  
298     The effects of testosterone treatment on body composition and metabolism in  
299     middle-aged obese men. *Int J Obes.* 1992;16(12): 991–7.
- 300           9.     Corona G, Mannucci E, Forti G, Maggi M. Following the common  
301     association between testosterone deficiency and diabetes mellitus, can testosterone

- 302 be regarded as a new therapy for diabetes? *Int J Androl.* 2009;32(5): 431–41.
- 303 10. American Diabetes Association. 2. Classification and diagnosis of  
304 diabetes: Standards of medical care in diabetes-2021. *Diabetes Care.* 2021;44: S15-  
305 33.
- 306 11. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca  
307 VA, Garber AJ, et al. American Association of Clinical Endocrinologists and  
308 American College of Endocrinology Guidelines for Management of Dyslipidemia  
309 and Prevention of Cardiovascular Disease. *Endocr Pract.* 2017;23: 1–87.
- 310 12. Lemeshow S, Hosmer DW, Klar J, Lwanga SK. Adequacy of Sample  
311 Size in Health Studies. WHO. West Sussex: John Wiley & Sons, Ltd; 1990.
- 312 13. IBM. IBM SPSS Statistics for Windows, Version 20.0. NY: IBM Corp.;  
313 2011.
- 314 14. Jarow JP, Espeland MA, Lipshultz LI. Evaluation of the azoospermic  
315 patient. *J Urol.* 1989;142(1): 62–5.
- 316 15. Hernández Uribe L, Hernández Marín I, Cervera-Aguilar R, Ayala AR.  
317 [Frequency and etiology of azoospermia in the study of infertile couples]. *Ginecol*  
318 *Obstet Mex.* 2001;69: 322–6. Spanish.
- 319 16. Esteves SC. Clinical management of infertile men with nonobstructive  
320 azoospermia. *Asian J Androl.* 2015;17: 459–70.
- 321 17. Hamada AJ, Esteves SC, Agarwal A. A comprehensive review of  
322 genetics and genetic testing in azoospermia. *Clinics.* 2013;68(Suppl 1): 39–60.
- 323 18. Liu PY, Handelsman DJ. The present and future state of hormonal

- 324 treatment for male infertility. *Hum Reprod Update*. 2003;9(1): 9–23.
- 325 19. Ramalingam M, Kini S, Mahmood T. Male fertility and infertility.  
326 *Obstet Gynaecol Reprod Med*. 2014;24(11): 326–32.
- 327 20. Bobjer J, Naumovska M, Giwercman YL, Giwercman A. High  
328 prevalence of androgen deficiency and abnormal lipid profile in infertile men with  
329 non-obstructive azoospermia. *Int J Androl*. 2012;35: 688–94.
- 330 21. Mendoza SG, Osuna A, Zerpa A, Gartside PS, Glueck CJ.  
331 Hypertriglyceridemia and hypoalphalipoproteinemia in azoospermic and  
332 oligospermic young men: Relationships of endogenous testosterone to triglyceride  
333 and high density lipoprotein cholesterol metabolism. *Metabolism*. 1981;30(5): 481–  
334 6.
- 335 22. Calonge RN, Kireev R, Guijarro A et al. L dysregulation in seminal  
336 and follicular fluids could be related with male and female infertility. *Lipid*  
337 *Dysregulation in Seminal and Follicular Fluids could be Related with Male and*  
338 *Female Infertility*. *Endocrinol Metab Int J*. 2018;6(1): 68–74.
- 339 23. Laaksonen DE, Niskanen L, Punnonen K, Nyysönen K, Tuomainen T-  
340 P, Valkonen V-P, et al. Testosterone and sex hormone-binding globulin predict the  
341 metabolic syndrome and diabetes in middle-aged men. *Diabetes Care*. 2004;27(5):  
342 1036–41.
- 343 24. Blouin K, Després J-P, Couillard C, Tremblay A, Prud'homme D,  
344 Bouchard C, et al. Contribution of age and declining androgen levels to features of  
345 the metabolic syndrome in men. *Metabolism*. 2005;54(8): 1034–1040.

- 346           25.    Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, et al.  
347    Type 2 diabetes mellitus and testosterone: a meta-analysis study. *Int J Androl.*  
348    2011;34(6 Pt 1): 528–40.
- 349           26.    Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, et al.  
350    Testosterone and metabolic syndrome: a meta-analysis study. *J Sex Med.* 2011;8(1):  
351    272–83.
- 352           27.    Yassin MM, Lubbad AMH, Taha AZ, Laqqan MM, Samar M.  
353    Testosterone and Gonadotropins in Infertile Men with Sertoli Cell Only Syndrome  
354    from Gaza Strip. *J Med.* 2017;18(1): 21–6.
- 355           28.    Gul U, Turunc T, Haydardedeoglu B, Yaycioglu O, Kuzgunbay B,  
356    Ozkardes H. Sperm retrieval and live birth rates in presumed Sertoli-cell-only  
357    syndrome in testis biopsy: a single centre experience. *Andrology.* 2013;1(1): 47–  
358    51.
- 359
- 360